Clinical Trial

Psilocybin After Trauma Surgery for Pain

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are: 1. Is a single psilocybin dose feasible to administer during postoperative hospitalization? 2. Is psilocybin safe in this patient population? 3. How does psilocybin affect postoperative pain, opioid use, anxiety, and depression after hospital discharge? Participants will: Receive one oral dose of psilocybin during their postoperative inpatient stay Complete assessments of pain, mood, and opioid use during recovery
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-08 -> 2029-04 2026-08-07
minor Completion pushed: 2027-08 -> 2029-08 2026-08-07
Trial Details
NCT Number NCT07406828
Lead Sponsor Trent Emerick
Collaborators: The Beckwith Institute
Conditions Pain Management, Postoperative Pain
Enrollment 70 participants
Start Date 2027-12-31
Primary Completion 2029-04 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-06